BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zorevunersen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zorevunersen\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06872125-9001@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Zorevunersen: Phase 3 readout est. (NCT06872125)
DESCRIPTION:Zorevunersen\, phase 3\, Dravet Syndrome.\nStudy: A Double-blin
 d Study Evaluating the Efficacy\, Safety\, and Tolerability of Zorevunerse
 n in Patients With Dravet Syndrome\nEstimated primary completion: March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zorevunersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06872125
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04740476-9001@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zorevunersen: Phase 2 readout est. (NCT04740476)
DESCRIPTION:Zorevunersen\, phase 2\, Dravet Syndrome.\nStudy: An Open-Label
  Extension Study of STK-001 for Patients With Dravet Syndrome\nEstimated p
 rimary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zorevunersen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04740476
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
